RLAY News and Press, Relay Therapeutics Inc. From 11/03/22

Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society for Medical Oncology (ESMO) Congress $1.1 billion in cash, cash eq...

Summary Relay Therapeutics' RLY-2608 is the first pan-allosteric PIKCA mutation inhibitor and has shown promise in preclinical studies, including better safety vs. Piqray (competition). Phase 1 dose escalation data for RLY-2608 is expected in the first half of 2023. The product ca...

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2022 fina...

Barclays has launched its coverage on Relay Therapeutics, Inc. ( NASDAQ: RLAY ) with an Equal Weight rating and a $23 price target, noting that the Cambridge, Massachusetts-based biotech remains fairly valued despite upcoming catalysts. The analyst Peter Lawson awaits init...

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to participate in a virtu...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time. Similarly, biotech stocks can ...

Summary Relay Therapeutics completed what was at the time the 3rd largest Biotech IPO in history in 2020, raising $400m. The company promised to use cutting edge AI driven technology to identify and develop drug targets with a primary focus on precision oncology. Its share pri...

Relay Therapeutics ( NASDAQ: RLAY ) is down 2.78% after-hours on pricing an underwritten public offering of 11,320,755 shares of its common stock at a public offering price of $26.50/share for expected gross proceeds to be ~$300.0M. Underwriters are granted a 30-day op...

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwri...

Medicine company Relay Therapeutics ( NASDAQ: RLAY ) has commenced an underwritten public offering of $300M shares. Additionally, the underwriters can also be granted a 30-day option to purchase up to an additional 15% of the shares offered in the public offering. RLAY...